ABSTRACT
Introduction
Exportin 1 (XPO1) is overexpressed in several solid tumors, and is associated with poor prognosis. Here, we aimed to evaluate the implication of XPO1 expression in solid tumors through a meta-analysis.
Methods
PubMed, Web of Science, and Embase databases were searched for articles published until February 2023. Statistical data of the patients, odds ratios and hazard ratios (HRs), together with their corresponding 95% confidence intervals (CIs) were pooled to assess clinicopathological features and survival outcomes. Besides, the Cancer Genome Atlas (TCGA) was used to explore the prognostic significance of XPO1 in solid tumors.
Results
A total of 22 works, comprising 2595 patients were included in this study. The results suggested that increased XPO1 expression was associated with a higher tumor grade, more lymph node metastasis, advanced tumor stage, and progressively worse total clinical stage. Additionally, high XPO1 expression was associated with worse overall survival (OS) (HR = 1.43, 95% CI = 1.12–1.81, P = 0.004) and shorter progression-free survival (HR = 1.40, 95% CI = 1.07–1.84, P = 0.01). An analysis using the TCGA dataset showed that high XPO1 expression was associated with poor OS and disease-free survival.
Conclusions
XPO1 is a promising prognostic biomarker and may constitute a therapeutic target for solid tumors.
PROSPERO registration number: CRD42023399159
Declaration of interest
The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
Declaration of interest
Peer reviewers on this manuscript have no relevant financial relationships or otherwise to disclose.
Availability of data and materials
All data generated or analyzed in this study are included in this article.
Supplementary Material
Supplemental data for this article can be accessed online at https://doi.org/10.1080/14737159.2023.2224505